SG11202007471WA - Granzyme b directed imaging and therapy - Google Patents
Granzyme b directed imaging and therapyInfo
- Publication number
- SG11202007471WA SG11202007471WA SG11202007471WA SG11202007471WA SG11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA
- Authority
- SG
- Singapore
- Prior art keywords
- granzyme
- therapy
- directed imaging
- imaging
- directed
- Prior art date
Links
- 102000001398 Granzyme Human genes 0.000 title 1
- 108060005986 Granzyme Proteins 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862629949P | 2018-02-13 | 2018-02-13 | |
US201862724433P | 2018-08-29 | 2018-08-29 | |
PCT/US2019/017802 WO2019160916A1 (en) | 2018-02-13 | 2019-02-13 | Granzyme b directed imaging and therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007471WA true SG11202007471WA (en) | 2020-09-29 |
Family
ID=67619639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007471WA SG11202007471WA (en) | 2018-02-13 | 2019-02-13 | Granzyme b directed imaging and therapy |
Country Status (10)
Country | Link |
---|---|
US (2) | US11667645B2 (en) |
EP (1) | EP3752145A4 (en) |
JP (1) | JP2021512964A (en) |
KR (1) | KR20200120712A (en) |
CN (1) | CN112261939A (en) |
AU (1) | AU2019220633A1 (en) |
CA (1) | CA3091016A1 (en) |
MX (1) | MX2020008408A (en) |
SG (1) | SG11202007471WA (en) |
WO (1) | WO2019160916A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019220633A1 (en) | 2018-02-13 | 2020-08-27 | Cytosite Biopharma Inc. | Granzyme B directed imaging and therapy |
EP3924354A1 (en) * | 2019-02-13 | 2021-12-22 | Cytosite Biopharma Inc. | Granzyme b directed imaging and therapy |
CN113512090A (en) * | 2021-04-30 | 2021-10-19 | 复旦大学附属肿瘤医院 | Granzyme B binding compound, precursor compound thereof and application |
CN116589527B (en) * | 2023-04-25 | 2023-12-12 | 北京大学第一医院 | Granzyme B targeted inhibitor, nuclear medicine probe and application |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002245649A1 (en) * | 2001-03-02 | 2002-09-19 | Idun Pharmaceuticals, Inc. | Methods, compositions and kits for preserving antigenicity |
JP2005522430A (en) * | 2002-02-04 | 2005-07-28 | メルク エンド カムパニー インコーポレーテッド | Granzyme B inhibitor |
WO2006017295A2 (en) * | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
EP2648735A4 (en) * | 2010-12-06 | 2014-07-30 | Univ British Columbia | Granzyme b inhibitor compositions, methods and uses for promoting wound healing |
WO2014139014A1 (en) * | 2013-03-15 | 2014-09-18 | The University Of British Columbia | Methods and compositions for the inhibition of vascular endothelial growth factor activity and vascular permeability |
US9605021B2 (en) * | 2013-03-29 | 2017-03-28 | Vida Therapeutics Inc. | Indoline compounds as granzyme B inhibitors |
WO2018005926A1 (en) * | 2016-07-01 | 2018-01-04 | The General Hospital Corporation | Granzyme b directed imaging and therapy |
AU2019220633A1 (en) | 2018-02-13 | 2020-08-27 | Cytosite Biopharma Inc. | Granzyme B directed imaging and therapy |
-
2019
- 2019-02-13 AU AU2019220633A patent/AU2019220633A1/en active Pending
- 2019-02-13 CA CA3091016A patent/CA3091016A1/en active Pending
- 2019-02-13 MX MX2020008408A patent/MX2020008408A/en unknown
- 2019-02-13 WO PCT/US2019/017802 patent/WO2019160916A1/en unknown
- 2019-02-13 SG SG11202007471WA patent/SG11202007471WA/en unknown
- 2019-02-13 JP JP2020564816A patent/JP2021512964A/en active Pending
- 2019-02-13 KR KR1020207026379A patent/KR20200120712A/en unknown
- 2019-02-13 US US16/969,823 patent/US11667645B2/en active Active
- 2019-02-13 EP EP19753648.5A patent/EP3752145A4/en active Pending
- 2019-02-13 CN CN201980021902.4A patent/CN112261939A/en active Pending
-
2023
- 2023-04-25 US US18/306,558 patent/US20230257388A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2020008408A (en) | 2020-10-28 |
AU2019220633A1 (en) | 2020-08-27 |
WO2019160916A1 (en) | 2019-08-22 |
CA3091016A1 (en) | 2019-08-22 |
US20200369673A1 (en) | 2020-11-26 |
EP3752145A1 (en) | 2020-12-23 |
KR20200120712A (en) | 2020-10-21 |
US20230257388A1 (en) | 2023-08-17 |
CN112261939A (en) | 2021-01-22 |
US11667645B2 (en) | 2023-06-06 |
JP2021512964A (en) | 2021-05-20 |
EP3752145A4 (en) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3478162A4 (en) | Granzyme b directed imaging and therapy | |
SG11202007471WA (en) | Granzyme b directed imaging and therapy | |
IL283511A (en) | Dendrimer for therapy and imaging | |
GB201807410D0 (en) | Diagnostic method and therapy | |
GB201713284D0 (en) | Therapy and diagnostics | |
GB201814040D0 (en) | Testing and therapy | |
GB201812388D0 (en) | Therapeutic and diagnostic target | |
GB201804219D0 (en) | Therapeutic and diagnostic target | |
GB201804127D0 (en) | Therapeutic and diagnostic target | |
GB201804125D0 (en) | Therapeutic and diagnostic target | |
GB201804126D0 (en) | Therapeutic and diagnostic target | |
GB201803925D0 (en) | Therapeutic and diagnostic target | |
GB201803921D0 (en) | Therapeutic and diagnostic target | |
GB201803934D0 (en) | Therapeutic and diagnostic target | |
GB201803830D0 (en) | Therapeutic and diagnostic target | |
GB201803840D0 (en) | Therapeutic and diagnostic target | |
GB201803374D0 (en) | Therapeutic and diagnostic target | |
GB201720788D0 (en) | Therapeutic and diagnostic target | |
GB201806133D0 (en) | Methods and medical uses | |
GB201716948D0 (en) | Therapeutic and diagnostic target | |
GB201716947D0 (en) | Therapeutic and diagnostic target | |
GB201716945D0 (en) | Therapeutic and diagnostic target | |
GB201716949D0 (en) | Therapeutic and diagnostic target | |
GB201712533D0 (en) | Therapeutic and diagnostic target | |
IL257210A (en) | System and |